





# Framework for the engagement of all health care providers in the management of drug resistant tuberculosis

WHO Library Cataloguing-in-Publication Data

Framework for the engagement of all health care providers in the management of drug resistant tuberculosis.

I.Tuberculosis, Multidrug-Resistant – prevention and control. 2.Public Sector. 3.Private Sector. 4.Organizations. 5.Delivery of Health Care. I.World Health Organization.

ISBN 978 92 4 150891 9 (NLM classification: WF 200)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: <a href="mailto:bookorders@who.int">bookorders@who.int</a>).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (<a href="www.who.int/about/licensing/copyright-form/en/index.html">www.who.int/about/licensing/copyright-form/en/index.html</a>).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Printed by the WHO Document Production Services, Geneva, Switzerland

Editing and design by Cadman Editing Services

Cover illustration copyright 123RF Stock Photo

WHO/HTM/TB/2015.04

# **Contents**

Abbreviations and acronyms	I
Acknowledgements	2
Foreword	
Executive summary	4
Glossary	
I. Rationale and purpose	6
<ol> <li>Approaches to engagement of relevant care providers and partners in PPM DR-1</li> </ol>	
2.1 Engaging individual health-care providers	
2.1.1 Referral of patients for diagnosis and treatment of DR-TB	
2.1.2 Provision of DOT based on a patient-centred care approach, treatment follow-up and social support 2.1.3 Diagnosis and treatment of DR-TB	t15
2.2 Engaging public or private laboratories	17
2.2.1 Diagnosis and referral of DR-TB patients for treatment	
2.2.2 Quality assurance for DST	
2.3 Engaging public or private health institutions (e.g. hospital, or medical or health centre)	19
2.3.1 Diagnosis, initiation of treatment, and selection of a provider for patient-centred DOT and case management	10
2.3.2 Diagnosis, treatment and management of DR-TB	
2.4 Engaging NGOs, professional associations or societies, affected groups, or other public or private organizations	r
2.4.1 Providing patient support	
2.4.2 Coordinating PPM implementation	
2.4.3 Advocacy, resource mobilization, prevention and management of stigma and discrimination, regulation linkage with existing social protection mechanisms	
3 Planning and implementing PPM DR-TB	
3.1 National situational assessment	29
3.2 Development of a scale-up plan for PPM DR-TB as part of the national strategic plan for TB	3 29
3.2.1 Mapping potential providers for PPM DR-TB	
3.2.2 Defining PPM DR-TB approaches that are relevant for each type of potential provider	
3.2.4 Mobilizing funds for scale-up of PPM DR-TB activities	
3.3 Development of the national operational guidelines and tools for PPM DR-TB	
3.4 Implementation of PPM DR-TB activities	
3.4.1 Preparation	
3.4.2 Training	33
3.4.3 Logistic arrangements	
3.4.4 Monitoring and evaluation	
Annex I	37
References	38

# **Abbreviations and acronyms**

ADR adverse drug reaction

CAP-TB Control and Prevention of Tuberculosis

DOH department of health

DOT directly observed treatment

DOTS core approach underpinning the Stop TB strategy for TB control

DR-TB drug-resistant tuberculosis
DS-TB drug-susceptible tuberculosis

DST drug susceptibility testing
FLD first-line tuberculosis drug

Global Fund Global Fund to Fight AIDS, Tuberculosis and Malaria

GP general practitioner

M&E monitoring and evaluation

MDR-TB multidrug-resistant tuberculosis
MMA Myanmar Medical Association

MMD/MOJ Main Medical Department of the Ministry of Justice (Azerbaijan)

MOH ministry of health

MOU memorandum of understanding

MSF Médecins Sans Frontières

NGO nongovernmental organization

NSP national strategic plan

NTP national tuberculosis programme

PhilCAT Philippine Coalition Against Tuberculosis

PMDT programmatic management of drug-resistant tuberculosis

PPM public-private mix (can also be public-public mix or private-private mix)

PPM DR-TB public-private mix for the management of drug-resistant tuberculosis

PPM DS-TB public—private mix for the management of drug-susceptible tuberculosis

PSI Population Services International

QA quality assurance

R&R recording and reporting

RR-TB rifampicin-resistant tuberculosis

SA service agreement

SLD second-line tuberculosis drug
SOP standard operating procedure

TB tuberculosis

WHO World Health Organization

# **Acknowledgements**

The development of this framework was coordinated by Linh Nguyen under the supervision of Ernesto Jaramillo, Mukund Uplekar, Fraser Wares and Karin Weyer of the WHO Global TB Programme. The contribution of the following experts and technical groups is gratefully acknowledged.

Expert group for development of the framework: Gabriel Akang, Ayyed Mohan Muneam Al-Dulaimi, Sheila Anazonwu, Kya Jai Maug Aung, Tran Ngoc Buu, Jacob Creswell, Pierpaolo De Colombani, Abdul Ghafoor, Krzysztof Herboczek, Pham Huyen Khanh, Saira Khowaja, SS Lal, Evan Lee, Seher Musaonbasioglu, Richard Muthoka, Wilfred AC Nkhoma, Seref Özkara, Mamel I Quelapio, Kwang-il Rim, Vivian Sanchez-Lofranco, Mohamed Awad Tageldin, Julia Tainijoki-Seyer, Jacques van den Broek, Anna Volz and Gini Williams.

WHO headquarters, Geneva, Switzerland: Vineet Bhatia, Ernesto Jaramillo, Linh Nguyen, Mukund Uplekar, Fraser Wares and Karin Weyer.

External reviewers: Jeremiah Chakaya, Medea Gegia, Cornelia Hennig, Philip Hopewell, Md Akramul Islam, Amy Sarmiento, Pedro Guillermo Suarez and William Wells.

Other people who provided support to the country assessments and documentation of best practices on engagement of health-care providers and partners for management of drug-resistant tuberculosis: Ayodele O Awe, Samiha Baghdadi, Erwin Cooreman, Md Khurshid Alam Hyder, Tauhid Islam, Asker Ismayilov, Ghulam Nabi Kazi, Mehmet Kontas, Woojin Lew, Gidado Mustapha, S Murat Mutlu, Bo Myint, Eva Nathanson, Rafael Alberto Lopez Olarte, Ejaz Qadeer, Alayo Sopekan, Zafar Toor, Ayşegül Yıldırım and Moe Zaw.

Funding from the United States Agency for International Development through USAID-WHO Consolidated Grants No. GHA-G-00-09-00003/US-2013-0580.

### **Foreword**

Global efforts to further improve case detection, treatment and care for drug-resistant tuberculosis (DR-TB) are urgently needed. In 2013, only 45% of the estimated 300 000 cases of patients with multidrug-resistant TB (MDR-TB; i.e. resistance to at least rifampicin and isoniazid) were detected among all notified pulmonary TB cases worldwide. The missing 55% of MDR-TB cases were either not detected or were managed outside of the national tuberculosis programmes (NTPs) and therefore not reported. In addition, the gap between diagnosis and treatment is growing rapidly in a number of countries. This is due to a rapid expansion of diagnostic capacity that has not been matched by an increase in management capacity. Hence, patients diagnosed with MDR-TB are being placed on "waiting lists" for treatment with second-line drugs. Finally, treatment outcomes for MDR-TB are poor, with only 48% successfully treated in the cohort of MDR-TB patients in 2011.

Public—private mix (PPM) for TB care and control has been implemented and scaled up in many countries. PPM initiatives in a number of high TB burden countries have regularly demonstrated increased case notification and levels of treatment success equal to those seen in the effective public sector. In 2013, non-NTP health-care providers contributed a significant proportion (up to 40%) of the notified TB cases in several countries or settings.

In a major milestone for the history of TB control, in May 2014, the End TB Strategy was adopted by the World Health Assembly of WHO. The End TB Strategy highlights that if we continue with business as usual, ending the TB epidemic will remain a long distant dream. PPM is something that cuts across the three pillars and the 10 components of the new strategy. In particular, it calls for the "... early diagnosis and universal drug susceptibility test (DST)..." (Component IA), "... treatment of all people with TB including DR-TB ..." (Component IB), "... engagement of all public and private care providers ..." (Component 2B) and "... Universal Health Coverage and regulatory frameworks ..." (Component 2C). We need to prepare and start working immediately on all these areas if we are to achieve the new target of ending TB established by the World Health Assembly.

Engaging all relevant health-care providers in the management of DR-TB cases is an important intervention to achieve the goal of universal access to DR-TB care and services. Although good practices of PPM DR-TB have been demonstrated in different countries and settings, overall progress in engaging non-NTP health-care providers remains limited. The objectives of the *Framework for engagement of all health-care providers in the management of drug-resistant tuberculosis* are to describe the rationale of, the approaches to, and best practices in engagement of different health providers and partners in the management of DR-TB patients; and to describe the necessary components in planning and implementation of PPM DR-TB activities. This document, that must be seen as one of the complementary recommendations that WHO is issuing to support implementation of the End TB Strategy, will help guide NTPs and partners in rolling-out of PPM DR-TB approaches in different countries and settings.

**Dr Mario Raviglione** 

Director of Global TB Programme
World Health Organization

### **Executive summary**

The Framework for engagement of all health-care providers in the management of drug-resistant tuberculosis has been developed to support countries in the implementation of public—private mix (PPM) for drug-resistant tuberculosis (DR-TB). This document complements other guidance and practical tools on PPM for TB control and prevention. It serves as a guidance document for countries in engaging providers and partners from outside the national TB programmes (NTPs) to address the complexity of the programmatic management of DR-TB.

The framework describes approaches for engaging different health-care providers and partners in diverse aspects of DR-TB care and management, including clinical care, public health tasks, patient-centred care, advocacy, funding mobilization, regulation and social protection. It describes the engagement of non-NTP providers and partners, which is not limited to diagnosis and treatment, but also includes other important aspects of DR-TB care, depending on the capacity and preference of the non-NTP providers and partners.

Approaches to engagement in PPM DR-TB are described by category of health-care provider: individual health-care providers (physician or non-physician individuals); public or private health institutions (e.g. hospital, or medical or health centre); public or private laboratories; nongovernmental organizations (NGOs); professional associations or societies; affected groups; and other public or private organizations. Each approach includes a description, eligibility, potential roles of the health provider, roles of the NTP, implementation considerations and case studies.

The case studies present and highlight best practices in PPM DR-TB in different countries and settings. They have been collected during in-country assessments and reflect contributions from colleagues in the NTPs, the WHO country and regional offices, and other partners working in the area. However, the case studies presented in the document do not represent all the PPM DR-TB best practices currently ongoing; rather, they provide a snapshot of what is happening. To add to the body of evidence presented in the document, a webpage hosted by the WHO Global TB Programme will serve as a repository that will be regularly updated with additional case studies contributed by NTPs and PPM DR-TB partners around the world.

The last section of the framework describes the necessary components or steps for planning and implementation of PPM DR-TB, for adoption by NTPs and partners, and adaptation for their specific settings. An assessment tool (see *Annex I*), will support national situational assessments, which are crucial for informing the planning of PPM DR-TB in each country or setting.

预览已结束,完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5 27225

